Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elvitegravir in HIV-1 Infected Pediatric Subjects
NCT01923311Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Aug 2013
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of elvitegravir in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Started Aug 2013; status: terminated.
02
Drugs
elvitegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01923311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01923311.